Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -566.69% | -751.27% | -439.39% | -189.76% | 287.73% |
| Total Depreciation and Amortization | 13.52% | 27.22% | 56.59% | 74.64% | -1.76% |
| Total Amortization of Deferred Charges | 117.94% | 53.24% | 2.86% | -30.73% | 2,395.24% |
| Total Other Non-Cash Items | 1,038.24% | 775.40% | 761.68% | 269.31% | -125.10% |
| Change in Net Operating Assets | -53.60% | 649.73% | 488.92% | 409.37% | 228.73% |
| Cash from Operations | -50.99% | -56.97% | -43.56% | 2.91% | 17.02% |
| Capital Expenditure | 80.40% | 85.00% | 132.99% | -140.05% | -164.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.22% | -445.54% | -445.54% | 65.29% | 65.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -289.58% | -107.70% | 1.16% | 29.56% | 49.35% |
| Cash from Investing | 66.31% | -167.33% | -49.36% | 59.02% | 60.61% |
| Total Debt Issued | 3,312.39% | 3,312.39% | 15.38% | -99.66% | -99.70% |
| Total Debt Repaid | -152.74% | -230.23% | -302.36% | 60.27% | 83.93% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.58% | 4.66% | -56.90% | -185.21% | -168.05% |
| Foreign Exchange rate Adjustments | 13.01% | -10.41% | -108.80% | -63.84% | 4,038.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -0.43% | -380.45% | -305.12% | -230.16% | -177.91% |